Read the full press release here: https://accure.health/accure-therapeutics-awarded-e1-million-from-spanish-government-to-evaluate-act-03-for-post-traumatic-epilepsy/  

Read the full press release here: Peptomyc has been granted 40.000 € within the ACTIVA startups  

You can read full text here: https://www.globenewswire.com/news-release/2024/04/25/2869327/0/en/deepull-unveils-1-hour-direct-from-blood-multiplex-PCR-test-for-95-of-sepsis-causing-pathogens-at-ESCMID-2024.html

In an era where digital transformation is reshaping healthcare, the industry is experiencing a significant shift towards more patient-centered services. AI-based virtual assistance is at the forefront of this transformation, providing seamless, efficient, and personalized guidance at symptom onset. Its role in facilitating patient engagement is becoming increasingly indispensable for every stakeholder in the healthcare ecosystem. You can read the full article here: https://www.mediktor.com/es/news/news/why-your-company-needs-an-ai-assistant-patient-engagement-from-first-contact  

Barcelona, Spain, March 21st, 2024 Peptomyc S.L., a clinical stage company specialized in the development of protein therapeutics targeting the MYC oncoprotein for cancer treatment, today announced the appointment of Dr. Selwyn Ho, MB, BS, to its Board of Directors. Giacomo Di Nepi, Chairman of Peptomyc, says: “We are delighted to have Selwyn joining us. His impressive track record in the Healthcare sector, together with his experience in different executive…

OMO-103 is an inhibitor for MYC, one of the most wanted, long-considered, undruggable oncogenes. The trial has established the safety, tolerability and pharmacokinetic profile of OMO-103, advising on Ph2 design and identifying soluble factors with the potential as pharmacodynamic and predictive response markers. https://www.nature.com/articles/s41591-024-02805-1.epdf?sharing_token=Kb6gG5E9yqkeIKGERvlDs9RgN0jAjWel9jnR3ZoTv0PbA8JGCp8lm6FKJ7Jh-32YH7J2xVsk_KGC2EJRU1fEovpCc4NhoH9mLlaGUrqCoPgvJZNKyZVnNLFM1UXLoCexi1Zxi7bZ2rOl-ZxWgZOy8orQl2v1yuum2gO9zR0Zarg%3D  

You can read the whole article here: https://mybinxhealth.com/news/binx-health-Enters-into-National-Distribution-Agreement-with-Cardinal-Health-to-Increase-Access    

Peptomyc is proud to announce that the results of the MYCure clinical trial have just been published in Nature Medicine Published today in Nature Medicine: Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial  

Binx health announced today it has entered into a non-exclusive national distribution agreement with Fisher Healthcare, a part of Thermo Fisher Scientific, to expand the rollout of the CLIA-waived, FDA-cleared binx io, which will increase access to care and improve the timely diagnosis of chlamydia (CT) and gonorrhea (NG). Read more

InBrain Neuroelectronics announced today that it received FDA breakthrough device designation for its intelligent network modulation system. You can read the whole new here: InBrain Neuroelectronics wins FDA breakthrough nod for intelligent network modulation system